The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft modelsSarah V. Holt, Paul D. Smith|British Journal of Cancer|2012Cited by 111